Tag: Endogenous polyamine / NMDA modulator

Agmatine (4-aminobutylguanidine) is an endogenous cationic amine produced by the decarboxylation of L-arginine via the mitochondrial enzyme arginine decarboxylase. First isolated in 1910 by the Nobel laureate Albrecht Kossel from herring sperm protamine hydrolysates, agmatine was rediscovered in 1994 as an endogenous mammalian neuromodulator synthesized, stored in synaptic vesicles, and released in a calcium-dependent manner from neurons in the hippocampus, hypothalamus, locus coeruleus, and other brain regions. The compound operates through a pharmacologically unusual multi-target profile: it produces voltage-dependent blockade of NMDA receptor-gated cation channels at an intrachannel pore site (IC50 approximately 300 micromolar); it binds with high affinity to imidazoline I1 receptors (Kd approximately 0.7 micromolar) and I2 receptors (Kd approximately 1 micromolar); it activates alpha-2 adrenoceptors (Kd approximately 4 micromolar); and it competitively inhibits inducible nitric oxide synthase (Ki approximately 220 micromolar) with selectivity over the neuronal and endothelial isoforms. This composite mechanism produces neuroprotective, analgesic, antidepressant, and anti-inflammatory activity across a broad range of preclinical models, including excitotoxic and ischemic neuronal injury, traumatic brain injury, neuropathic and inflammatory pain, and behavioral models of depression and anxiety.

Clinical evidence, though still early-phase and limited in scale, has demonstrated efficacy of oral agmatine sulfate in lumbar disc-associated radiculopathy in a randomized, double-blind, placebo-controlled trial at 2,670 mg per day for 14 days, with statistically significant pain reduction versus placebo [1]. A pilot open-label case series in painful small fiber neuropathy reported approximately 46 percent mean pain reduction over two months at the same dose [2]. A 2026 prospective open-label case series at Massachusetts General Hospital reported preliminary evidence for agmatine sulfate augmentation in treatment-resistant obsessive-compulsive disorder, with 40 percent of patients achieving clinically meaningful improvement on the Yale-Brown Obsessive Compulsive Scale [3]. Preclinical antidepressant-like activity has been demonstrated in the forced swimming test and tail suspension test across multiple laboratories, mediated through NMDA receptor blockade, nitric oxide synthase inhibition, and AMPA receptor and mTOR signaling activation. The compound modulates opioid pharmacology in a biphasic manner: it potentiates acute morphine analgesia while preventing the development of analgesic tolerance and physical dependence, a profile that has attracted substantial research interest in the context of the opioid crisis.

Safety data are favorable. A long-term safety case report documented 5 years of continuous daily intake at 2.67 g agmatine sulfate with no adverse events, and postmarketing surveillance of 1,015 individuals consuming the same regimen for periods of 3 weeks to 3 years identified no adverse events [4]. Clinical trial adverse events have been limited to mild, transient gastrointestinal symptoms (nausea, diarrhea, abdominal discomfort) at the highest studied doses. The compound is commercially available as a dietary supplement (agmatine sulfate) in multiple jurisdictions. This monograph reviews the chemistry, biosynthesis, and multi-target pharmacology of agmatine; the pharmacokinetic profile including oral bioavailability and CNS distribution; the preclinical and clinical evidence base across neuropathic pain, depression, neuroprotection, and opioid modulation; sourcing and quality considerations; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five mechanistically related compounds against agmatine on five competency standards.